Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

Trial Profile

Effect of Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Autoimmune disorders; Type 1 diabetes mellitus
  • Focus Therapeutic Use

Most Recent Events

  • 15 Oct 2018 Planned End Date changed from 1 Jan 2019 to 1 Jun 2021.
  • 15 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Dec 2020.
  • 12 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Jan 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top